The clinical effectiveness of erythromycin for patients with diffuse panbronchiolitis (DPB) The best of three expiratory efforts was analyzed and compared with the predicted values.8
The clinical effectiveness of erythromycin for patients with diffuse panbronchiolitis (DPB) was previously rec¬ ognized. However (Fig 4) .
Following treatment with erythromycin, the CT scores decreased significantly compared with pre¬ treatment scores (p<0.01). The posttreatment CT scores decreased in 13 of 18 erythromycin-treated patients compared with the pretreatment (Table 2 ). In the individual categories of CT findings, the scores for the extent of small nodular opacities and that of mucoid impaction and the severity of periairway thickening were significantly reduced after erythro¬ mycin therapy (small nodular opacities, p<0.01; mucoid impaction, p=0.016; periairway thickening, p<0.01). However, the scores for the severity and extent of airway ectasia showed no significant de¬ crease after treatment (Table 3) .
Discussion
The identification of specific and more clinically relevant pathologic changes in pulmonary diseases has been made possible by CT 
